KR100335564B1 - Diat food composition for reducing body fat with growth hormone releasing enhancer - Google Patents
Diat food composition for reducing body fat with growth hormone releasing enhancer Download PDFInfo
- Publication number
- KR100335564B1 KR100335564B1 KR1019990032624A KR19990032624A KR100335564B1 KR 100335564 B1 KR100335564 B1 KR 100335564B1 KR 1019990032624 A KR1019990032624 A KR 1019990032624A KR 19990032624 A KR19990032624 A KR 19990032624A KR 100335564 B1 KR100335564 B1 KR 100335564B1
- Authority
- KR
- South Korea
- Prior art keywords
- body fat
- diet
- growth hormone
- food
- reducing body
- Prior art date
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 37
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 22
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 12
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 12
- 239000000122 growth hormone Substances 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 title 1
- 239000003623 enhancer Substances 0.000 title 1
- 235000005911 diet Nutrition 0.000 claims abstract description 38
- 230000037213 diet Effects 0.000 claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 18
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims abstract description 7
- 239000004475 Arginine Substances 0.000 claims abstract description 7
- 229920001661 Chitosan Polymers 0.000 claims abstract description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004472 Lysine Substances 0.000 claims abstract description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960004203 carnitine Drugs 0.000 claims abstract description 7
- 229940045110 chitosan Drugs 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 4
- 235000019156 vitamin B Nutrition 0.000 claims description 4
- 239000011720 vitamin B Substances 0.000 claims description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 235000007882 dietary composition Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 230000001882 diuretic effect Effects 0.000 abstract description 7
- 230000004580 weight loss Effects 0.000 abstract description 5
- 230000036528 appetite Effects 0.000 abstract description 4
- 235000019789 appetite Nutrition 0.000 abstract description 4
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract description 3
- -1 B 3 Chemical compound 0.000 abstract description 2
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 239000003324 growth hormone secretagogue Substances 0.000 description 4
- 230000003880 negative regulation of appetite Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 3
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000476 body water Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0606—Arginine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/063—Lysine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 아르기닌, 라이신, 원지추출물 및 사상자 추출물중을 주재로 하되, 여기에 키토산, 카르니틴 및 비타민 B2, B3, B5, B6및 C를 적절히 혼합하여 이루어진 체지방 감소용 다이어트 식품조성물에 관한 것이다. 본 발명의 다이어트 식품은 기존의 다이어트 식품들이 갖는 여러 부작용, 예를들어 이뇨작용에 의한 급격한 체중감소라든가 식욕억제, 근력감소 또는 요요현상과 같은 부작용이 전혀 없고 일상의 음식을 충분히 섭취하면서도 체지방은 감소시키고 근골격은 증가시켜주는 전형적인 성장호르몬의 다이어트 효과를 나타내는 아주 이상적인 다이어트 식품이다.The present invention is based on arginine, lysine, raw extract and casualty extract, but chitosan, carnitine and vitamin B 2 , B 3 , B 5 , B 6 and C in a diet for food composition for reducing body fat It is about. The diet food of the present invention has no side effects, such as rapid weight loss due to diuretic action, such as a diuretic effect, such as suppressing appetite, muscle strength or yo-yo phenomenon, and eating enough daily food while reducing body fat It is an ideal diet food that shows the effect of the typical growth hormone diet that increases the musculoskeletal.
Description
본 발명은 성장호르몬 분비촉진 소재를 함유한 체지방 감소용 다이어트 식품조성물에 관한 것이다. 더욱 구체적으로, 본 발명적은 기존의 다이어트 식품들이 갖는 여러 부작용, 예를들어 이뇨작용에 의한 수분감소로 인한 급격한 체중감소라든가 식욕억제, 근력감소 또는 다이어트 중단시 발생하는 요요현상과 같은 부작용이 전혀 없고 일상의 음식을 충분히 섭취하면서도 체지방은 감소시키고 근골격은 증가시켜주는 전형적인 성장호르몬의 다이어트 효과를 나타내는 아주 이상적인 다이어트 식품 조성물에 관한 것이다.The present invention relates to a diet food composition for reducing body fat containing growth hormone secretagogue material. More specifically, the present invention does not have any side effects such as rapid weight loss due to diminishing water content due to diuretic action or appetite suppression, muscle strength reduction or yo-yo phenomenon occurring when the diet is stopped. It is a very ideal diet food composition that shows the dietary effect of typical growth hormone to reduce the body fat and increase the musculoskeletal while eating enough daily food.
성장호르몬은 사람과 동물의 뇌하수체 전엽에서 분비되는 단백질성 호르몬으로서 생체 내에서의 주된 기능은 간 등 말초조직에서 인슐린 유사성장인자(Insulin-like growth factor-1, IGF-1)를 생성케 하여 인슐린유사 성장인자로 하여금 연골조직에 작용하여 뼈의 성장을 자극하게 하고, 대사작용을 통해서 단백질 합성작용을 증가시킴으로서 근육을 증가시키고 동시에 지방조직으로부터 지방산의 산화를 촉진시켜 체지방을 감소시키는 기능이 있다. 이러한 기능으로 성장호르몬은 오래전부터 왜소증 환자들의 치료목적으로 사용되어 왔고 근래에는 비만치료제로도 많이 사용되고 있는 실정이다.Growth hormone is a protein hormone secreted by the anterior pituitary gland of humans and animals. The main function in vivo is to produce insulin-like growth factor-1 (IGF-1) in peripheral tissues such as the liver. Similar growth factors act on cartilage tissue to stimulate bone growth and increase protein synthesis through metabolism to increase muscles and at the same time promote the oxidation of fatty acids from adipose tissue to reduce body fat. With this function, growth hormone has been used for the treatment of dwarfism patients for a long time, and recently, it is also widely used as an obesity treatment agent.
그러나 지금까지 비만치료제용 성장호르몬은 자체가 거대 단백질이어서 경구투여가 불가능하고 주사기를 이용한 근육주사로 이루어 지는데, 유전자 재조합방식에 의해 대량 생산됨에도 불구하고 치료 기간동안 많은 비용이 요구되며 근육내 주사로 인한 불편함이 클 뿐만 아니라 과량 투여시선단비대증, 동화스테로이드 효과(anabolic steroid effects), 부종 등을 야기시킬 수 있고 에스트로겐(estrogen)처럼 암유발 가능성에 대한 우려도 있는 것이 사실이다.However, until now, growth hormone for obesity treatments is a huge protein itself, which cannot be orally administered and consists of intramuscular injection using a syringe. It is true that not only the discomfort caused by the drug can be excessive, but it can also cause hypertrophy, anabolic steroid effects, edema, etc., and there is concern about the possibility of cancer like estrogen.
한편, 기존 다이어트 식품들 대부분은 이뇨작용이라든가 식욕억제 효능이 있는 소재들을 사용함으로서 급격한 수분감소로 인한 쇼크라든가 식욕 억제에 의한 영양불균형 및 복부팽만감에 따른 불쾌감 또는 근력감퇴에 의한 무력감 등 여러 부작용을 지니고 있다.On the other hand, most of the existing diet foods have various side effects such as diuretic action or appetite suppressant effect, such as shock due to rapid water loss, nutritional imbalance due to appetite suppression, discomfort caused by bloating, or helplessness due to muscle weakness. have.
이에 본 발명자들은 상술한 선행기술의 문제점을 해결하기 위해 수많은 연구와 실험을 거듭한 결과 이뇨작용이나 식욕억제 효능이 있는 소재를 이용하지 않고 성장호르몬 분비촉진 소재를 다이어트 식품에 사용함으로서 기존의 다이어트 식품들이 갖는 여러 부작용, 예를들어 이뇨작용에 의한 급격한 체중감소라든가 식욕억제, 근력감소 또는 요요현상과 같은 부작용이 전혀 없을 뿐만아니라 주사제형 비만치료제용 성장호르몬이 갖는 문제점들을 완전히 해결한 아주 이상적인 체지방 감소용 다이어트 식품을 개발하게 되었다.Accordingly, the present inventors have conducted numerous studies and experiments to solve the above-mentioned problems of the prior art, and thus, by using growth hormone secretion materials in diet foods without using diuretic or appetite suppressing effects, diet foods have been used. Have no side effects such as rapid weight loss due to diuresis, loss of appetite, muscle strength or yo-yo, as well as the ideal body fat reduction that completely solves the problems of growth hormone for injectable obesity Has developed a diet for food.
제 1도는 본 발명의 다이어트 식품을 복용한 남성의 다이어트 효과를 나타낸 것이다.Figure 1 shows the diet effect of men who took the diet food of the present invention.
제 2도는 본 발명의 다이어트 식품을 복용한 여성의 다이어트 효과를 나타낸 것이다.Figure 2 shows the diet effect of women who took the diet food of the present invention.
본 발명은 아르기닌, 라이신, 원지추출물 및 사상자추출물을 성장호르몬 분비 촉진 소재로 하고 여기에 키토산, 카르니틴 및 비타민 B군과 C를 첨가하여 이루어짐을 특징으로 하는 체지방 감소용 다이어트 식품 조성물에 관한 것이다.The present invention relates to a dietary food composition for reducing body fat, comprising arginine, lysine, native extract and filamentous extract as growth hormone secretion promoting material, and chitosan, carnitine and vitamin B group and C added thereto.
본 발명에 따르면 성장호르몬 분비촉진 효과가 있는 아미노산인 아르기닌(arginine)과 라이신(lysine), 그리고 본 발명자들이 성장호르몬 분비촉진제로 개발한 원지추출물 또는 사상자추출물(대한민국 특허출원 제98-53921호 참조)을 주재로 하되 여기에 지방흡수억제 효과가 있는 키토산(chitosan)과 체지방 분해촉진 효과가 있는 카르니틴(L-caritine) 및 보조제로서 비타민 B2, B3, B5, B6및 C를 적절히 혼합하여 체지방 감소용 다이어트 식품 또는 음료조성물에 제조된다.According to the present invention, arginine and lysine, which are amino acids having a growth hormone secretion effect, and the extracts or filamentous extracts developed by the present inventors as growth hormone secretagogues (see Korean Patent Application No. 98-53921) In addition to chitosan (fat absorption inhibitory effect) and carnitine (L-caritine) and adjuvant supplements, vitamin B 2 , B 3 , B 5 , B 6 and C are properly mixed It is prepared in a dietary food or beverage composition for reducing body fat.
본 발명에 따른 다이어트 식품조성물은 아르기닌 20-50중량%, 라이신 5-20중량%, 원지추출물 2-10중량%, 사상자 추출물 2-10중량%, 키토산 5-15중량%, 카르니틴 10-40중량% 및 비타민 B군 및 C군 0.001-2 중량% 함유하는 것이 바람직하다.Diet food composition according to the present invention is 20-50% by weight of arginine, 5-20% by weight of lysine, 2-10% by weight of extract extract, 2-10% by weight of filamentous extract, 5-15% by weight of chitosan, 10-40% by weight of carnitine % And 0.001-2% by weight of vitamins B and C are preferable.
본 발명에 따른 다이어트 식품조성물은 기존의 다이어트 식품들이 갖는 대표적인 부작용, 이뇨작용이라든가 식욕억제 효능이 있는 소재들을 사용함으로서 급격한 수분감소로 인한 쇼크라든가 식욕억제에 의한 영양불균형 및 복부팽만감에 따른 불쾌감 또는 근력감퇴에 의한 무력감 등과 같은 부작용이 전혀 없고 일상의 음식을 충분히 섭취하면서도 체지방은 크게 감소시키고 근골격은 증가시켜주는 전형적인 성장호르몬의 다이어트 효과를 나타내는 아주 이상적인 체지방 감소용 다이어트 식품이다.Diet food composition according to the present invention by using a representative side effect, diuretic action or appetite suppressing effect of the existing diet foods due to a sudden decrease in moisture due to rapid moisture loss or malaise due to nutritional imbalance and bloating due to appetite suppression It has no side effects such as helplessness due to decay, and is a very ideal body fat reduction diet food that shows the dietary effect of typical growth hormone which greatly reduces body fat and increases musculoskeletal while consuming enough daily food.
본 발명에 따른 다이어트 식품의 형태는 분말형태는 물론 음료형태도 포함하며, 분말형태의 경우 캡슐로 포장하면 더욱 효과적이다.The form of the diet food according to the present invention includes not only powder form but also beverage form, and in the case of powder form, it is more effective to pack it in capsules.
이하 본 발명을 실시예에 의거하여 구체적으로 설명하지만, 본 발명의 기술적 범위가 이들 실시예로 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples, but the technical scope of the present invention is not limited to these Examples.
실시예 1. 원지, 사상자 추출물의 제조방법Example 1. Preparation of raw paper, filamentous extract
건조된 원지, 사상자를 일반 한약도매상에서 구입하여 각각에 과량의 물을 첨가하여 80∼100℃로 2시간 이상 추출한 후 여과하여 얻은 여액을 농축, 동결건조하여 각각의 추출물을 얻었다.Dried paper and casualties were purchased from a general Chinese wholesaler, and excess water was added to each extract, followed by extraction at 80-100 ° C. for 2 hours or more, and the filtrate obtained by filtration was concentrated and lyophilized to obtain respective extracts.
실시예 2. 체지방 감소용 다이어트 식품의 제조방법Example 2. Method of producing a diet food for reducing body fat
아르기닌(20-50 중량%), 라이신(5-20 중량%), 원지추출물(2-10 중량%), 사상자추출물(2-10 중량%), 키토산(5-15 중량%), 카르니틴(10-40 중량%) 및 보조제로서 비타민 B2, B3, B5, B6및 C(0.001-2 중량%)를 믹서로 충분히 혼합한 후 캡슐충진기(모델 KS-1, 대산기계공업)를 이용 하드캡슐 No.1(서흥캡슐)에 약 300㎎씩 충진하여 캡슐형 다이어트 식품을 제조하였다. 대조군으로 사용할 위약(이하 placebo)은 덱스트린을 캡슐에 충진하여 제조하였다.Arginine (20-50% by weight), lysine (5-20% by weight), raw extract (2-10% by weight), filamentous extract (2-10% by weight), chitosan (5-15% by weight), carnitine (10 -40% by weight) and vitamin B 2 , B 3 , B 5 , B 6 and C (0.001-2% by weight) as a supplement thoroughly mixed with a capsule filling machine (model KS-1, Daesan Machinery Co., Ltd.) About 300 mg each of the used hard capsule No. 1 (seoheung capsules) was filled to prepare a capsule-type diet food. Placebo (herebo) to be used as a control was prepared by filling dextrin in capsules.
실시예 3. 다이어트 효과측정Example 3. Diet Effect Measurement
비만인 성인 남녀 60명을 비만도, 즉 평균 체지방률이 비슷하게 placebo 처리군(남성 15 명, 여성 15명)과 다이어트 식품 처리군(남성 15명, 여성 15명)으로 나누고 평상시 식생활을 그대로 유지하면서 상기 실시예 2에서 제조한 다이어트 식품 또는 placebo를 6캡슐씩 2회 매일 복용토록 한 후 3개월간 경시에 따른 체지방량, 근골격, 체수분량, 체중, 혈중지질 등의 변화를 측정하였다. 체지방량, 근골격 및 체수분량은 생체전기저항법(Bioelectrical Impedance Assay)의 원리를 이용한 체지방측정기(모델 GIF-991, 길우트레이딩)로 측정하였고 최종 혈중지질의 변화는 대한민국 충남 청주시 모병원에 의뢰하여 측정하였다.The above 60 adult men and women were divided into placebo treatment group (15 males, 15 females) and diet food treatment group (15 males, 15 females) with similar obesity, ie, average body fat percentage, while maintaining the usual diet as described above. After taking two capsules of the diet food or placebo prepared in 2 twice daily, the body fat, musculoskeletal, body water, weight, and blood lipids were measured for three months. Body fat, musculoskeletal and body water were measured using a body fat analyzer (model GIF-991, Gilwoo Trading) using the principle of Bioelectrical Impedance Assay. .
그 측정 결과를 각 군별 평균치로 하여 하기 표 1, 2, 3, 4, 및 5에 나타내었다.The measurement results are shown in Tables 1, 2, 3, 4, and 5 below as average values for each group.
상기 표들에서 보는 바와 같이 본 발명의 다이어트 식품은 약 9주정도 꾸준히 복용할 경우 남녀를 불문하고 체수분 감소현상 없이 체지방 감소 효과가 특히 탁월할 뿐만 아니라 근골격을 다소 증가시켜주는 아주 이상적인 체지방 감소용 다이어트 식품임을 확인할 수 있다.As shown in the above table, the diet food of the present invention is a very ideal body fat reduction diet food that increases the musculoskeletal effect as well as the body fat reduction effect is particularly excellent without the body moisture reduction phenomenon regardless of men and women when taking about 9 weeks steadily You can see that.
상기 표 3에서 알 수 있듯이 본 발명에 따른 다이어트 식품의 체중 감소효과는 남성에 비해 여성의 경우가 더 큰 효과를 나타냈는데 그 원인으로는 아무래도 여성에 비해 남성이 활동성이 크고 그에 따른 근골격 증가량이 여성에 비해 크기 때문에 그 만큼 체중 감소 효과는 낮게 나타난 것이다.As can be seen in Table 3 above, the weight loss effect of the diet food according to the present invention showed a greater effect in the case of women than in men. The weight loss effect is low because it is larger than that.
또한 상기 표 5에서 보는 바와 같이 본 발명의 다이어트 식품은 성인병의 주요원인이 될 수 있는 혈중 중성지질(Triglyceride)도 Placebo에 비해 크게 감소시킴을 알 수 있다.In addition, the diet food of the present invention, as shown in Table 5, it can be seen that the blood triglycerides (Triglyceride) which can be a major cause of the adult disease is significantly reduced compared to Placebo.
이상에서 살펴본 바와 같이 본 발명의 다이어트 식품은 이뇨작용이나 식욕억제 효능이 있는 소재를 이용하지 않고 성장호르몬 분비촉진 소재를 사용함으로서 기존의 다이어트 식품들이 갖는 여러 부작용, 예를들어 급격한 수분감소로 인한 쇼크라든가 식욕억제에 의한 영양불균형 및 복부팽만감에 따른 불쾌감 또는 근력감퇴에 의한 무력감 등과 같은 부작용이 전혀 없고 일상의 음식을 충분히 섭취하면서도 체지방은 크게 감소시키고 근골격은 증가시켜주는 전형적인 성장호르몬의 다이어트 효과를 나타내는 아주 이상적인 체지방 감소용 다이어트 식품이다.As described above, the diet food of the present invention uses growth hormone secretagogue materials without using diuretic or appetite suppressing effects, so that various side effects of conventional diet foods, for example, shock due to rapid water loss There are no side effects such as nutritional imbalance due to appetite suppression, bloating caused by abdominal bloating or weakness due to muscle weakness. It is an ideal diet for reducing body fat.
또한 본 발명에 따른 다이어트 식품 조성물은 성장호르몬 분비촉진 소재를 주재로 사용함으로서 체지방 감소를 목적으로 하는 제품 이외에 성장기 어린이를 위한 성장촉진용 식품이나 음료 또는 성인병 예방 및 노화억제용 식품이나 음료로도 이용할 수 있다.In addition, the dietary food composition according to the present invention can be used as a growth promoting food or beverage for growing children or as a food or beverage for preventing adult diseases and aging, in addition to products aimed at reducing body fat by using growth hormone secretagogue as a main ingredient. Can be.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019990032624A KR100335564B1 (en) | 1999-08-09 | 1999-08-09 | Diat food composition for reducing body fat with growth hormone releasing enhancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019990032624A KR100335564B1 (en) | 1999-08-09 | 1999-08-09 | Diat food composition for reducing body fat with growth hormone releasing enhancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20010017229A KR20010017229A (en) | 2001-03-05 |
| KR100335564B1 true KR100335564B1 (en) | 2002-05-08 |
Family
ID=19606622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019990032624A KR100335564B1 (en) | 1999-08-09 | 1999-08-09 | Diat food composition for reducing body fat with growth hormone releasing enhancer |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100335564B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004112511A3 (en) * | 2003-06-26 | 2005-04-07 | Donald M Mcleod | Supplement for restoring growth hormone levels |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100504124B1 (en) * | 2001-05-18 | 2005-07-27 | 한국 한의학 연구원 | Mixture for prevention of obesity |
| EP1583547B1 (en) * | 2002-12-27 | 2009-09-23 | Korea Institute of Oriental Medicine | Anti-obesity ingredients from medicinal plants and their composition |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH067117A (en) * | 1992-03-24 | 1994-01-18 | Kirin Brewery Co Ltd | Inhibitor of diet lipid digestive absorption and food/ beverage containing the same |
| EP0775450A2 (en) * | 1995-11-24 | 1997-05-28 | Ar Trade-Invest SA | Dietetic compositions comprising chitosan |
| EP0841011A1 (en) * | 1996-10-23 | 1998-05-13 | SIRC S.p.A. NATURAL & DIETETIC FOODS | Dietary preparation comprising chitosan and other soluble fibres combined with ascorbic acid, organic chromium, vanadium and garcinia hydroxycitrate for lipid absorption lowering and glucide metabolism stabilization |
| KR0142725B1 (en) * | 1995-02-11 | 1998-07-01 | 김광배 | Drinks containing chitosan |
| JPH11253130A (en) * | 1998-03-13 | 1999-09-21 | Nippon Kayaku Co Ltd | Diet food |
| JP2000069939A (en) * | 1998-08-31 | 2000-03-07 | Kankyo System:Kk | Health food |
| KR20000031430A (en) * | 1998-11-06 | 2000-06-05 | 이정상 | Preparation of health food containing herb medicines |
-
1999
- 1999-08-09 KR KR1019990032624A patent/KR100335564B1/en not_active IP Right Cessation
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH067117A (en) * | 1992-03-24 | 1994-01-18 | Kirin Brewery Co Ltd | Inhibitor of diet lipid digestive absorption and food/ beverage containing the same |
| KR0142725B1 (en) * | 1995-02-11 | 1998-07-01 | 김광배 | Drinks containing chitosan |
| EP0775450A2 (en) * | 1995-11-24 | 1997-05-28 | Ar Trade-Invest SA | Dietetic compositions comprising chitosan |
| EP0841011A1 (en) * | 1996-10-23 | 1998-05-13 | SIRC S.p.A. NATURAL & DIETETIC FOODS | Dietary preparation comprising chitosan and other soluble fibres combined with ascorbic acid, organic chromium, vanadium and garcinia hydroxycitrate for lipid absorption lowering and glucide metabolism stabilization |
| JPH11253130A (en) * | 1998-03-13 | 1999-09-21 | Nippon Kayaku Co Ltd | Diet food |
| JP2000069939A (en) * | 1998-08-31 | 2000-03-07 | Kankyo System:Kk | Health food |
| KR20000031430A (en) * | 1998-11-06 | 2000-06-05 | 이정상 | Preparation of health food containing herb medicines |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004112511A3 (en) * | 2003-06-26 | 2005-04-07 | Donald M Mcleod | Supplement for restoring growth hormone levels |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010017229A (en) | 2001-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011100294A4 (en) | Formulations and treatments for trichology | |
| JP2009533331A (en) | Novel use of compounds and combinations of compounds to improve physical appearance | |
| JP2004250445A (en) | Glycation inhibitor and its use | |
| ES2340510T3 (en) | USE OF RENTAL-FURANS FOR THE PREPARATION OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF OBESITY AND FOR THE COSMETIC TREATMENT OF THE EXCEESS OF WEIGHT. | |
| US7674484B2 (en) | Dietary supplement including He Shou Wu, parasitic loranthus and green tea to promote weight loss | |
| JP2010202520A (en) | Skin improver and oral composition for cosmetic and health purposes | |
| JP2007254440A (en) | Lipid metabolism-adjusting agent and lipid metabolism-adjusting food | |
| KR100725926B1 (en) | Feed containing garlic for chicken | |
| KR100335564B1 (en) | Diat food composition for reducing body fat with growth hormone releasing enhancer | |
| JP3459932B2 (en) | Anti-osteoporosis composition | |
| JP2010159283A (en) | Proanthocyanidin-containing composition | |
| KR0182396B1 (en) | Nutrients for a diet | |
| KR20170054116A (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
| JP2006069967A (en) | Gray hair-suppressing composition and cosmetics including the same and eating and drinking type cosmetics | |
| KR100419121B1 (en) | A functional food Containing herbes composition for female menopausal disorder | |
| KR101840547B1 (en) | Manufacturing method of a chicken foot jelly and the chicken foot jelly | |
| KR102322276B1 (en) | Beverage composition for preventing obesity and relieving edema | |
| JP5341422B2 (en) | Antioxidant composition containing bee candy and royal jelly | |
| CN102754674A (en) | Liver-protecting and health-care loach freeze-dried flour and making method thereof | |
| Kakkar et al. | How Can Flaxseed be Utilized as Functional Food | |
| WO2021074807A1 (en) | Nutritional supplement | |
| US20180325915A1 (en) | Chlorophyll composition | |
| KR100848213B1 (en) | Tribulus terrestris l. extract having growth hormone secretion accelerating function | |
| WO2004082697A1 (en) | Compositions of natural products and use thereof | |
| EP4162814A1 (en) | Composition for fatigue recovery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130318 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20140306 Year of fee payment: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20160411 Year of fee payment: 15 |
|
| FPAY | Annual fee payment |
Payment date: 20170330 Year of fee payment: 16 |
|
| FPAY | Annual fee payment |
Payment date: 20190402 Year of fee payment: 18 |
|
| EXPY | Expiration of term |